Compounds > bleomycin a6
Page last updated: 2024-12-11

bleomycin a6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bleomycin A6: forms conjugate with monoclonal antibody anti-CCT2 which binds to leukemia cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9877229
CHEMBL ID1231529
MeSH IDM0149402

Synonyms (19)

Synonym
CHEMBL1231529
pingyangmycin a6
bleomycinamide, n1-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-
boanmycin
bleomycin a6
bleomycinamide, n(sup 1)-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-
n(sup 1)-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)bleomycinamide
zhengguangmycin a6
37293-17-7
0b19ocb220 ,
unii-0b19ocb220
bleomycinamide, n1-(3-((4-((3- aminopropyl)amino)butyl)amino)propyl)-
bleomycin a6 [who-dd]
[(2s,3r,4r,5s,6s)-2-[(3r,4r,5r,6r)-2-[(1r,2s)-2-[[6-amino-2-[(1s)-3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2s,3r,4r)-5-[[(2r,3s)-1-[2-[4-[4-[3-[4-(3-aminopropylamino)butylamino]propylcarbamoyl]-1,3-
(2r,3s,4s,5r,6r)-2-{[(2r,3s,4s,5s,6s)-2-{[(1r,2s)-2-[({6-amino-2-[(1s)-3-amino-1-{[(2s)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl]-5-methylpyrimidin-4-yl}carbonyl)amino]-3-{[(1r,2s,3s)-4-{[(1s,2r)-1-{[2-(4-{[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl
Q27236557
DTXSID001318678
HY-147359
CS-0567262

Research Excerpts

Overview

Bleomycin A6 is an antineoplastic antibiotic.

ExcerptReferenceRelevance
"Bleomycin A6 is an antineoplastic antibiotic. "( [Preclinical pharmacologic evaluation of bleomycin A6].
Lin, FT, 1989)		1.99

Dosage Studied

ExcerptRelevanceReference
" At a tolerable dosage level, bleomycin A6 exerted remarkable growth inhibition on human colon cancer HT-29 and cecum cancer Hce-8693 xenografts (approximately 90% inhibition)."( [Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice].
Deng, Y, 1990)		0.88
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (20.00)18.7374
1990's13 (43.33)18.2507
2000's4 (13.33)29.6817
2010's6 (20.00)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.25 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.3920nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		2.3920mitomycinalkylating agent;
antineoplastic agent
hydroxyproline
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.		2.38204-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.0710fluorescein isothiocyanate
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		1.9710copper group element atom;
elemental gold
1,7-phenanthroline
[no description available]		1.9810phenanthroline
n-formylmethionine leucyl-phenylalanine
N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.		2.0110tripeptide
bleomycetin
bleomycetin: RN given refers to parent cpd		2.2510
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.07101,2-diacyl-sn-glycero-3-phosphocholine
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		2.0610
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		1.9810
zhengguangmycin
zhengguangmycin: antitumor antibiotic complex consisting of more than 10 components; produced by Streptomyces pingyangensis;		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Lung
[description not available]		04.0931
Lung Neoplasms
Tumors or cancer of the LUNG.		04.0931
Cancer of Liver
[description not available]		03.0950
Liver Neoplasms
Tumors or cancer of the LIVER.		03.0950
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0110
Experimental Neoplasms
[description not available]		02.0110
Cancer of Esophagus
[description not available]		02.0110
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.0110
Breast Cancer
[description not available]		04.3422
Cancer of Head
[description not available]		03.3811
Germinoblastoma
[description not available]		03.3811
Breast Neoplasms
Tumors or cancer of the human BREAST.		04.3422
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		03.3811
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		03.3811
Cancer of Colon
[description not available]		02.6830
Colonic Neoplasms
Tumors or cancer of the COLON.		02.6830
Cancer of Cecum
[description not available]		02.6730
Alveolitis, Fibrosing
[description not available]		02.3820
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		02.3820
Acute Lymphoid Leukemia
[description not available]		01.9810
Adenocarcinoma, Basal Cell
[description not available]		01.9810
Hepatocellular Carcinoma
[description not available]		02.6730
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9810
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.6730
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		01.9810
Carcinoma, Giant Cell
An epithelial neoplasm characterized by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid. (From Stedman, 25th ed & Segen, Dictionary of Modern Medicine, 1992)		01.9810
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		01.9810
Pyrexia
[description not available]		03.3711
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		03.3711
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		03.3711
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		03.3711
Colorectal Cancer
[description not available]		0210
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		0210
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		0210
Cancer of Pharynx
[description not available]		01.9710
Pharyngeal Neoplasms
Tumors or cancer of the PHARYNX.		01.9710
Leucocythaemia
[description not available]		02.3720
Experimental Leukemia
[description not available]		01.9610
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.3720